Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by TheIceMan3on Apr 09, 2020 12:49pm

94 Views

Post# 30894649

RE:c.AGN starting to gain traction once again....

and you haven't even mentioned the 'shrooms. That's the beauty of this company, it isn't just one thing they have going for them. Look where SHRM is at and how it's been doing. There is a lot of great things in store for AGN I believe!

luvhorses wrote: here's what's instore for AGN as it moves forward in the coming weeks:

Health Canada is interested so funds to help AGN's research team is in the cards. Ethics is submitted for chronic cough in Australia. Ethics is submitted in South Korea for COVID-19. Ethics going in soon for Australia for COVID-19. FDA registered trial on clinicaltrials.gov in the USA.